@article{d1fa1a4e840d4baabce4c4c686275fe5,
title = "Mutations in cdsA and pgsA Correlate with Daptomycin Resistance in Streptococcus mitis and S. Oralis",
abstract = "We investigated the ability of several recent clinical viridans group streptococci (VGS) bloodstream isolates (Streptococcus mitis/S. oralis subgroup) from daptomycin (DAP)-naive patients to develop DAP resistance in vitro. All strains rapidly developed high-level and stable DAP resistance. Substitutions in two enzymes involved in the cardiolipin biosynthesis pathway were identified, i.e., CdsA (phosphatidate cytidylyltransferase) and PgsA (CDP-diacylglycerol-glycerol-3-phosphate-3phosphatidyltransferase). These mutations were associated with complete disappearance of phosphatidylglycerol and cardiolipin from cell membranes. DAP interactions with the cell membrane differed in isolates with PgsA versus CdsA substitutions.",
keywords = "CdsA, Daptomycin resistance, PgsA, Streptococcus mitis",
author = "Tran, {Truc T.} and Mishra, {Nagendra N.} and Ravin Seepersaud and Lorena Diaz and Rafael Rios and Dinh, {An Q.} and Cristina Garcia-de-la-Maria and Rybak, {Michael J.} and Miro, {Jose M.} and Shelburne, {Samuel A.} and Sullam, {Paul M.} and Bayer, {Arnold S.} and Arias, {Cesar A.}",
note = "Funding Information: C.A.A. has received grant support from Merck Pharmaceuticals and MeMed Diagnostics. A.S.B. has received grant support from ContraFect Corporation and Intron Pharmaceuticals. N.N.M. has received grant support from Merck Pharmaceuticals. M.J.R. received research support, consulted, or was part of a speaker bureau for Allergan, Bayer, Cempra, Merck, The Medicines Company, Sunovian, and Theravance Biophar-maceutics. J.M.M. has received consulting honoraria and/or research grants from AbbVie, Angelini, Bristol-Myers Squibb, Jansen, Genentech, Medtronic, Merck, Novartis, Gilead Sciences, and ViiV HealthCare. Funding Information: This work was supported by University El Bosque and the National Institutes of Health (NIAID K24 AI121296 and R01 AI134637 to C.A.A., K08 AI113317 to T.T.T., 1R01130056-01 to A.S.B., and R01 AI41513 to P.M.S.; M.J.R. is supported in part by R01 AI121400 and R21 AI109266). C.A.A. is supported by the UTHealth Presidential Award and University of Texas STARS Award. J.M.M. is supported by grants REIPI RD06/0008 (the Spanish Network for Research in Infectious Diseases) and PI11/01131 (Instituto Carlos III, Ministerio de Econom{\'i}a y Competitividad). J.M.M. received a research grant from Institut d{\textquoteright}Investigacions Biom{\`e}diques August Pi I Sunyer (IDIBAPS) in 2017 to 2019 and the European Regional Development Fund (ERDF). N.N.M. was supported by LABiomed-Harbor UCLA intramural research grant 31604-01. Publisher Copyright: {\textcopyright} 2019 American Society for Microbiology. All Rights Reserved.",
year = "2019",
month = feb,
doi = "10.1128/AAC.01531-18",
language = "English (US)",
volume = "63",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "2",
}